Trial Profile
Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2014
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- 28 Aug 2014 New trial record